Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA, about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells (iPSCs).

While there are no currently available treatments capable of growing new hair follicles, Hamilton contends that iPSC-derived cells have the potential to help millions of people suffering from hair loss and to advance cell therapy capabilities across the industry.

"We're trying to get our first product into clinic, which is an autologous cell therapy-based approach to bioengineering hair follicles," Hamilton said. "It's probably going to be at least a couple of more years before we feel we're really ready."

Watch this video to learn more.

Japanese scientists grow hair in vitro
Japanese scientists have generated hair follicles in vitro and doing so could have implications for treating hair loss disorders, animal testing, and...

Pfizer to acquire Arena Pharmaceuticals
Pfizer will acquire all outstanding shares of Arena Pharmaceuticals for $100 per share in an all-cash transaction for a total equity value of approximately...